Navigation Links
Questcor to Report Fourth Quarter and Full Year 2010 Earnings and Conduct Conference Call on February 23, 2011
Date:2/7/2011

ANAHEIM, Calif., Feb. 7, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release financial results for the fourth quarter and full year ended December 31, 2010 on Wednesday, February 23, 2011 after the close of the U.S. financial markets.  The Company will host a conference call and webcast on Wednesday, February 23, 2011 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the fourth quarter and full year 2010, as well as current corporate developments.  This date is a schedule change from the Company's previously announced expectation to report fourth quarter and year-end results on February 22, 2011 announced in the January 10, 2011 press release.  Conference call details:Date:

Wednesday, February 23, 2011Time:

4:30 p.m. ETDial-in (U.S.):

877-941-6010Dial-in (International):

480-629-9772Web cast:

www.questcor.comTo access an audio replay of the call:Replay (U.S.):

800-406-7325Replay (International):

303-590-3030Replay Passcode:

4408313About QuestcorQuestcor Pharmaceuticals, Inc. is a biopharmaceutical company whose products help patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from two indications: the treatment of acute exacerbations of multiple sclerosis in adults and the treatment of infantile spasms in children under two years of age.  Questcor is also implementing plans to commercialize Acthar for use in treating nephrotic syndrome, another on-label indication. Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor also markets Doral® (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Pharmaceuticals Reports Strong Finish to 2010
2. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2011
3. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
4. Questcor to Present at the Maxim Group Growth Conference
5. Questcor Reports Third Quarter 2010 Results
6. Questcor to Present at the 21st Annual Oppenheimer Healthcare Conference
7. Questcor Teams With Child Neurology Foundation (CNF) to Fund Infantile Spasms Scientific Research
8. Questcor and Child Neurology Foundation Support the 2nd Annual Infantile Spasms (IS) Awareness Week
9. Questcor to Present at UBS Global Life Sciences Conference
10. Mitchell J. Blutt, M.D. Appointed to Questcor Board of Directors
11. Questcor Receives Notification of PDUFA Date Extension to September 11, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 22, 2017 Hologic, Inc. (Nasdaq: ... acquisition of Cynosure, Inc., a leader in medical aesthetics ... "We are pleased to complete our acquisition ... Michael Davin and the entire Cynosure team to ... medical aesthetics market," said Steve MacMillan , Hologic,s ...
(Date:3/22/2017)... -- TFS is pleased to announce the appointment of ... two global executive positions in Medical Affairs and Clinical Development. Dr. ... and will report to Dr. Montse Barceló , Chief Operating ... ... of medical and scientific expertise gained across leading biopharmaceutical companies and ...
(Date:3/22/2017)... 22, 2017  Levine Cancer Institute today launched ... designed to address lung cancer diagnosis, treatment and ... The mobile lung unit is the first-of-its-kind to ... treatment interventions through integrated mobile technology, traditional treatment ... barriers and a lack of public transportation are ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... ... College basketball surges to its peak during the March Madness NCAA tournament, but ... to be foster parents. Through a televised spot, Coach Self is inviting adults to ... abuse, neglect and other family challenges. People who respond to Self’s call to community ...
(Date:3/22/2017)... ... ... HumanHaus is proud to announce the launch of its newest invention on crowdfunding ... invented, but our customers today are busy, energetic, multi-taskers that live in a smarter ... and retired that want to travel. The Sweep&Stand is a self-standing broom ...
(Date:3/22/2017)... ... ... NYC Chiropractor Dr. Steven Shoshany recently helped host a seminar at his cutting edge ... focused on a new protocol for treating pain. Dr. Shoshany is among the first ... the first seminar in the country was hosted at his Integrated Chiropractic Practice. ...
(Date:3/22/2017)... , ... March 22, 2017 , ... Sharon Kleyne is ... more than two decades ago to research evaporation of earth’s and the body’s water ... better health. Also the host of the nationally syndicated radio program, The Sharon Kleyne ...
(Date:3/22/2017)... ... March 22, 2017 , ... The International Association of ... specialists and other medical professionals caring for those suffering from the full spectrum ... iaedp Symposium at the Green Valley Resort in Las Vegas, March 22 - ...
Breaking Medicine News(10 mins):